Trial Profile

Phase II trial of ramucirumab and docetaxel for previously treated NSCLC patients with malignant pleural effusion

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 16 Sep 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ramucirumab (Primary) ; Docetaxel
Indications Malignant pleural effusion; Non-small cell lung cancer
Focus Therapeutic Use
Acronyms PLEURAM
Sponsors Eli Lilly and Company

Most Recent Events

16 Sep 2022 New trial record
09 Aug 2022 Results (n=14; From September 2019 to February 2022) assessing efficacy and safety of ramucirumab and docetaxel for non small cell lung cancer patients with malignant pleural effusion, presented at the 2022 World Conference on Lung Cancer.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com